Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium
Preliminary Safety and Efficacy Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer will be presented ROCKVILLE, Md. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
Toggle Summary Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that Peter D. Suzdak , Ph.D., the Company's chief executive
Toggle Summary Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
ROCKVILLE, Md. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration agreement

Events & Presentations

Date Event Details
Summary Toggle Sep 6, 2018
9:35 AM EDT
Sep 6, 2018 9:35 AM EDT 09/06/18
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]

Summary Toggle Apr 14-18, 2018 Apr 14, 2018 04/14/18

Title: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 [View Poster]

Location

Chicago, Illinois


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy